Our group reported that TNFα-induced MUC4 is involved in HER2-targeted therapy resistance in vivo and in vitro, and that it is an independent predictor of trastuzumab response in HER2-positive breast cancer patients (115). Here, ERBB2 is linked to breast carcinoma.